Julia Weisinger, MD

home / authors / julia-weisinger-md

PhD candidate at Greater Paris University Hospitals

Articles

$Julia Weisinger, MD: Obinutuzumab a Promising Option for Intolerant/Refractory iTTP$

Julia Weisinger, MD: Obinutuzumab a Promising Option for Intolerant/Refractory iTTP

Victoria Johnson;Julia Weisinger, MD

December 19th 2024

Weisinger discussed findings from the largest cohort of patients with iTTP treated with Obinutuzumab.

Read More

Latest Updated Articles

Gursimran Kochhar, MD | Credit: Allegheny Health Network

Published: October 4th 2024 | Updated: October 14th 2024

Minimally Invasive Techniques to Manage Complex Polyps at Allegheny Health Network

HCPLive Cardiology Month in Review: April 2024

Published: May 2nd 2024 | Updated: May 6th 2024

Cardiology Month in Review: April 2024

Hide Okuno, MS: Tube Weaning Reduces Parental Stress, Findings Guide Future Studies

Published: November 16th 2024 | Updated: December 19th 2024

Hide Okuno, MS: Tube Weaning Reduces Parental Stress, Findings Guide Future Studies

Parent Stress Reduces Over Time When Weaning Child Off Tube Feeding with Hide Okuno, MS

Published: November 15th 2024 | Updated: December 19th 2024

Parent Stress Reduces Over Time When Weaning Child Off Tube Feeding with Hide Okuno, MS

Scott Bartley, MD I Credit: LinkedIn

Published: December 16th 2024 | Updated: December 19th 2024

Brilaroxazine Shows Long-Term Efficacy in Schizophrenia in Phase 3 RECOVER

FDA Approves Tapinarof 1% Cream for Adult, Pediatric Patients with Atopic Dermatitis

Published: December 16th 2024 | Updated: December 19th 2024

FDA Approves Tapinarof 1% Cream for Adult, Pediatric Patients with Atopic Dermatitis

Do Not Sell My Information

Terms & Conditions

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

© 2024 MJH Life Sciences

All rights reserved.